Holen Sie sich die Stockscreener-App
1.95
1.02%
-0.02
Vorhandelsmarkt:
1.95
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.97
Offen:
$2.155
24-Stunden-Volumen:
50.83M
Relative Volume:
3.98
Marktkapitalisierung:
$705.62M
Einnahmen:
$241.53M
Nettoeinkommen (Verlust:
$-389.92M
KGV:
-1.5854
EPS:
-1.23
Netto-Cashflow:
$-323.54M
1W Leistung:
-15.58%
1M Leistung:
-16.67%
6M Leistung:
-44.29%
1J Leistung:
-82.57%
1-Tages-Spanne:
$1.855
$2.20
1-Wochen-Bereich:
$1.855
$2.35
52-Wochen-Spanne:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.95 | 712.85M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveWeekly Stock Recap & Weekly High Return Forecasts - newser.com
What Wall Street predicts for Iovance Biotherapeutics Inc. stock priceExit Point & Intraday High Probability Setup Alerts - newser.com
Strategies to average down on Iovance Biotherapeutics Inc.July 2025 Action & Community Consensus Picks - newser.com
Iovance Stock Faces Tough Times - timothysykes.com
Iovance Shares Surge on Groundbreaking Lung Cancer Trial Results - AD HOC NEWS
Why Iovance Biotherapeutics Inc. stock is favored by top institutions - newser.com
Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug - MarketScreener
Why Iovance Biotherapeutics Inc. stock appeals to analystsQuarterly Market Summary & Daily Stock Trend Watchlist - newser.com
Why Iovance Biotherapeutics Inc. stock attracts global investors2025 Market Sentiment & Community Driven Trade Alerts - newser.com
Iovance (IOVA) Reports Promising Interim Results from Phase 2 Tr - GuruFocus
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersOptions Play & Free Expert Verified Stock Movement Alerts - newser.com
What insider trading reveals about Iovance Biotherapeutics Inc. stockJobs Report & Free Technical Pattern Based Buy Signals - newser.com
What MACD trends signal for Iovance Biotherapeutics Inc. (2LB) stockJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Automated trading signals detected on Iovance Biotherapeutics Inc.Weekly Trading Summary & Fast Gaining Stock Reports - newser.com
Iovance (NASDAQ: IOVA) lifileucel posts 26% ORR in NSCLC; mDOR not reached at 25.4 months - Stock Titan
How big funds are accumulating Iovance Biotherapeutics Inc. (2LB) stockOil Prices & Fast Entry and Exit Trade Plans - newser.com
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 Summary & Risk Managed Investment Signals - newser.com
Published on: 2025-11-03 05:20:39 - newser.com
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Gains Report & Consistent Profit Alerts - newser.com
Published on: 2025-11-03 03:17:06 - newser.com
Is it time to cut losses on Iovance Biotherapeutics Inc.2025 Breakouts & Breakdowns & Low Risk High Win Rate Picks - newser.com
Using portfolio simulators with Iovance Biotherapeutics Inc. includedMarket Growth Review & Weekly Watchlist for Hot Stocks - newser.com
Will Iovance Biotherapeutics Inc. stock gain from lower inflationWeekly Trend Recap & Step-by-Step Swing Trade Plans - newser.com
Can trapped investors hope for a rebound in Iovance Biotherapeutics Inc.July 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Iovance Biotherapeutics reports positive interim data for NSCLC therapy - Traders Union
Will Iovance Biotherapeutics Inc. stock beat EPS estimatesMarket Activity Summary & Free Daily Entry Point Trade Alerts - newser.com
Published on: 2025-11-02 22:26:15 - newser.com
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
Is Iovance Biotherapeutics Inc. stock poised for growthWeekly Risk Report & Trade Opportunity Analysis Reports - newser.com
Will Iovance Biotherapeutics Inc. stock see PE expansion2025 Price Action Summary & High Conviction Investment Ideas - newser.com
How Iovance Biotherapeutics Inc. stock trades during market volatilityJuly 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
Iovance Biotherapeutics, Inc. (IOVA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
HC Wainwright Issues Negative Forecast for IOVA Earnings - MarketBeat
Published on: 2025-11-01 04:05:22 - newser.com
Can Iovance Biotherapeutics Inc. stock deliver strong Q4 earnings2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Iovance Biotherapeutics (IOVA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):